These findings raise a question whether patients with IgAV should be followed frequently after the onset of purpura to detect nephritis in the early stages and whether assessment of biomarkers, such as Gd-IgA1- and Gd-IgA1-specific IgG autoantibodies, should be included. This evidence concerns the gene IGHA1 and nephritis.